Creative Planning’s Protara Therapeutics TARA Stock Holding History

Creative Planning’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-608	Closed	-$6K	–	2108
2019 Q3	$6K	Buy	+608	New	+$8.7K	﹤0.01%	1920

Other funds holding TARA

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning's TARA Position: Q4 2019 in Review

Creative Planning sold out of Protara Therapeutics (TARA) in Q4 2019, closing a stake of 608 shares — an estimated $6K sold.

Creative Planning first reported a position in TARA in Q3 2019 and held it in 1 quarter. The position peaked at $6K in Q3 2019. 16 funds tracked by Wall St. Rank hold TARA as of Q4 2019.

Creative Planning reported no remaining Protara Therapeutics position as of Q4 2019 after selling out during the quarter.
Creative Planning sold 608 Protara Therapeutics shares in Q4 2019, an estimated $6K.
Creative Planning first reported a position in Protara Therapeutics in Q3 2019 and held it in 1 quarter.
Creative Planning's Protara Therapeutics position peaked at $6K in Q3 2019.
16 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2019.

Based on Creative Planning's 13F filing for Q4 2019, filed 30 Jan 2020.